4761. Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee.
作者: H Shen.;H Sprott.;A Aeschlimann.;R E Gay.;B A Michel.;S Gay.;H Sprott.
来源: Rheumatology (Oxford). 2006年45卷6期765-70页
The study was designed to investigate the analgesic effects and mechanisms of acetaminophen (paracetamol) in symptomatic osteoarthritis (OA) of the knee.
4762. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model.
作者: J Delgado Alves.;L J Mason.;P R J Ames.;P P Chen.;J Rauch.;J S Levine.;R Subang.;D A Isenberg.
来源: Rheumatology (Oxford). 2005年44卷10期1238-44页
Oxidative stress contributes to atherosclerosis, and evidence of enhanced oxidative stress exists in antiphospholipid syndrome (APS). In a non-lupus murine model, we evaluated whether anticardiolipin (aCL) antibodies could affect the oxidant/antioxidant balance as an early biochemical step of APS.
4763. Molecular imaging: novel tools in visualizing rheumatoid arthritis.
作者: A Wunder.;R H Straub.;S Gay.;J Funk.;U Müller-Ladner.
来源: Rheumatology (Oxford). 2005年44卷11期1341-9页
Molecular imaging is a rapidly emerging field in biomedical research, aiming at the visualization, characterization and quantification of molecular and cellular processes non-invasively within intact living organisms. To sense biological processes such as gene expression, angiogenesis, apoptosis or cell trafficking in vivo, imaging reporter agents that interact specifically with molecular targets and appropriate imaging systems are currently under development. In rheumatoid arthritis, these novel tools will be used to evaluate physiological and pathophysiological processes, to facilitate diagnosis and monitor therapeutic regimens, to enable reliable prognosis and to support the development of new therapies. In this review, we summarize the basic principles of molecular imaging, such as the development of molecular imaging agents, the actual capabilities of different imaging modalities and the most recent advances in molecular imaging, demonstrating the potential of this technology. With regard to their applicability in rheumatic diseases, we discuss potential molecular targets, current experimental approaches and the future prospects for molecular imaging in rheumatoid arthritis.
4765. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome.
作者: L Kovács.;I Marczinovits.;A György.;G K Tóth.;L Dorgai.;J Pál.;J Molnár.;G Pokorny.
来源: Rheumatology (Oxford). 2005年44卷8期1021-5页
The authors have previously identified a peptide of the human muscarinic acetylcholine receptor-3 (m3AChR) as a suitable antigen for the immunodetection of antimuscarinic acetylcholine receptor autoantibodies in primary Sjögren's syndrome (pSS). The aim of this study was to assess the clinical correlations and disease specificity of these antibodies.
4766. Quality of care for NSAID users: development of an assessment tool.
作者: P Jobanputra.;V Arthur.;M Pugh.;F Spannuth.;P Griffiths.;E Thomas.;T Sheeran.
来源: Rheumatology (Oxford). 2005年44卷5期633-7页
Assessments of NSAID use based on authoritative guidelines typically overlook patients' views and nuances of medical history. Our objective was to develop an assessment tool that incorporates these aspects, and technical items, for quality of care assessments in NSAID users.
4767. Spa treatment for primary fibromyalgia syndrome: a combination of thalassotherapy, exercise and patient education improves symptoms and quality of life.
作者: T R Zijlstra.;M A F J van de Laar.;H J Bernelot Moens.;E Taal.;L Zakraoui.;J J Rasker.
来源: Rheumatology (Oxford). 2005年44卷4期539-46页
To study the effect of a combination of thalassotherapy, exercise and patient education in people with fibromyalgia.
4768. Endothelial cells, fibroblasts and vasculitis.
作者: Christopher D Buckley.;G Ed Rainger.;Gerard B Nash.;Karim Raza.
来源: Rheumatology (Oxford). 2005年44卷7期860-3页
One of the most important questions in vasculitis research is not why inflammation of blood vessels occurs but why it persists, often in a site-specific manner. In this review we illustrate how stromal cells, such as fibroblasts and pericytes, might play an important role in regulating the site at which vasculitis occurs. Smooth muscle cells and fibroblasts directly influence the behaviour of overlying vascular cells, amplifying the response of the endothelium to proinflammatory agents such as TNF-alpha and allowing enhanced and inappropriate leucocyte recruitment. An abnormal local vascular stromal environment can therefore influence local endothelial function and drive the persistence of local vascular inflammation. However, such local vascular inflammation can have distant effects on the systemic vascular system, leading to widespread endothelial cell dysfunction. Vascular endothelial dysfunction is common in a range of immune-mediated inflammatory diseases, is seen in multiple vascular beds, and is reversible following the induction of disease remission. The mechanisms that drive such systemic vascular endothelial dysfunction are unclear but factors such as TNF-alpha and CRP may play a role. Persistence of such widespread endothelial dysfunction in systemic vasculitis appears to have long-term consequences, leading to the acceleration of atherosclerosis and premature ischaemic heart disease. It may also underlie the accelerated atherosclerosis seen in other immune-mediated rheumatic diseases, such as rheumatoid arthritis.
4769. Localized scleroderma is an autoimmune disorder.
There have been many studies suggesting that localized scleroderma has a strong autoimmune background, although the lesions are usually limited to the skin and subcutaneous tissue. Here we summarize previous data on the autoimmunity of localized scleroderma, mostly published in the last two decades, because there has not been a review paper summarizing autoimmunity in this disorder.
4771. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age.
作者: S Rinaldi.;A Doria.;F Salaffi.;M Ermani.;L Iaccarino.;A Ghirardello.;S Zampieri.;P Sarzi-Puttini.;P F Gambari.;G Perini.
来源: Rheumatology (Oxford). 2004年43卷12期1574-9页
To examine health-related quality of life (HRQOL) in Italian patients with systemic lupus erythematosus (SLE) and compare it with that of healthy people, and to investigate relationships among different dimensions and subscales of a generic health status measure.
4772. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX.
作者: C Fiehn.;U Müller-Ladner.;S Gay.;S Krienke.;S Freudenberg-Konrad.;J Funk.;A D Ho.;H Sinn.;A Wunder.
来源: Rheumatology (Oxford). 2004年43卷9期1097-105页
To evaluate the anti-arthritic effects of the new inflammation-targeted drug MTX-HSA and to investigate whether peripheral blood mononuclear cells (PBMC) are potential target cells for albumin-mediated drug delivery.
4773. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
作者: T Stoll.;N Sutcliffe.;J Mach.;R Klaghofer.;D A Isenberg.
来源: Rheumatology (Oxford). 2004年43卷8期1039-44页
To determine whether initial damage, disease duration, age, initial health status, average disease activity over the 5 yr or an average medication score covering the follow-up period would predict an increase in damage in patients with systemic lupus erythematosus (SLE) within the next 5 yr.
4774. Versican splice variant messenger RNA expression in normal human Achilles tendon and tendinopathies.
作者: A N Corps.;A H N Robinson.;T Movin.;M L Costa.;D C Ireland.;B L Hazleman.;G P Riley.
来源: Rheumatology (Oxford). 2004年43卷8期969-72页
Versican is the principal large proteoglycan expressed in mid-tendon, but its role in tendon pathology is unknown. Our objective was to define the expression of versican isoform splice variant messenger ribonucleic acid (mRNA) in normal Achilles tendons, in chronic painful tendinopathy and in ruptured tendons.
4775. Population requirement for primary knee replacement surgery: a cross-sectional study.
作者: P Jüni.;P Dieppe.;J Donovan.;T Peters.;J Eachus.;N Pearson.;R Greenwood.;S Frankel.
来源: Rheumatology (Oxford). 2003年42卷4期516-21页
To determine the population requirement for total knee replacement (TKR) in England.
4776. Psychometric properties of a Dutch short form of the Arthritis Impact Measurement Scales 2 (Dutch-AIMS2-SF).
To evaluate the reliability and validity of a Dutch version of the Arthritis Impact Measurement Scales 2 short form (AIMS2-SF) and examine the agreement between the AIMS2 and AIMS2-SF in rheumatoid arthritis (RA) patients.
4777. Influence of obesity on the development of osteoarthritis of the hip: a systematic review.
作者: A M Lievense.;S M A Bierma-Zeinstra.;A P Verhagen.;M E van Baar.;J A N Verhaar.;B W Koes.
来源: Rheumatology (Oxford). 2002年41卷10期1155-62页
To evaluate the evidence for the influence of obesity as a risk factor for the occurrence of osteoarthritis (OA) of the hip.
4778. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors.
作者: S Bas.;T V Perneger.;M Seitz.;J-M Tiercy.;P Roux-Lombard.;P A Guerne.
来源: Rheumatology (Oxford). 2002年41卷7期809-14页
To examine the value of anti-cyclic citrullinated peptide (anti-CCP) antibodies, anti-keratin antibodies (AKA) and immunoglobulin M rheumatoid factors (IgM RF) in discriminating between rheumatoid arthritis (RA) and other rheumatic diseases, and to determine whether the clinical manifestations or severity of erosions in RA are associated with anti-CCP positivity.
4780. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study.
作者: V Gerloni.;R Cimaz.;M Gattinara.;C Arnoldi.;I Pontikaki.;F Fantini.
来源: Rheumatology (Oxford). 2001年40卷8期907-13页
This open prospective trial was performed in order to assess the efficacy and safety of cyclosporin A in the treatment of patients with juvenile chronic arthritis (JCA).
|